Chronic hepatitis B virus (HBV) is a debilitating infectious disease of the liver that afflicts over 250 million people worldwide and is a leading cause of chronic liver disease and liver transplants. It is a global epidemic that impacts more people than hepatitis C virus (HCV) and HIV infection combined, with a higher mortality and morbidity rate. An estimated 500,000 to one million people die every year from HBV-related causes.
The Centers for Disease Control (CDC) reports that approximately one and a half million people in the US are chronically infected with HBV. There is a high unmet need for curative therapies for chronic HBV—the current standard of care is unable to cure the condition in more than 90% of patients. Assembly is advancing multiple Core Protein Allosteric Modifiers (CpAMs) derived from distinct chemical series with a focus on increasing functional cure rates for…
